Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PALISADE BIO, INC.

(PALI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Palisade Bio, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2021

08/24/2021 | 08:15am EST

Palisade Bio, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported Loss from operations were $32,858,000 against $1,841,000 a year ago. Net loss was $31,746,000 against $1,851,000 a year ago. Basic loss per share were $3.59 against $0.67 a year ago. Diluted loss per share were $4.10 against $0.67 a year ago. For the six months, the company reported Loss from operations were $34,811,000 against $4,236,000 a year ago. Net loss was $35,776,000 against $4,235,000 a year ago. Basic loss per share were $6.17 against $1.53 a year ago. Diluted loss per share were $6.96 against $1.53 a year ago.


ę S&P Capital IQ 2021
All news about PALISADE BIO, INC.
11/30Palisade Bio to be Granted European Patent for Lead Drug Candidate LB1148 in December T..
MT
11/30Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug C..
AQ
11/23Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Inclu..
AQ
11/23PALISADE BIO, INC. : Change in Directors or Principal Officers, Submission of Matters to a..
AQ
11/15Palisade Bio Reports Third Quarter Financial Results
AQ
11/12PALISADE BIO, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
AQ
11/12Palisade Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended..
CI
10/28PALISADE BIO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
10/22PALISADE BIO : Announces Sale of Seneca Asset NSI-189 for the treatment of Central Nervous..
PU
10/22PALISADE BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on PALISADE BIO, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -29,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,63x
Yield 2021 -
Capitalization 27,0 M 27,0 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 10
Free-Float 81,8%
Chart PALISADE BIO, INC.
Duration : Period :
Palisade Bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PALISADE BIO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,99 $
Average target price 7,00 $
Spread / Average Target 252%
EPS Revisions
Managers and Directors
Thomas M. Hallam Chief Executive Officer & Director
J. D. Finley Chief Financial Officer
Ryker Willie Finance Director & Controller
James R. Neal Chairman
John Rodenrys Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
PALISADE BIO, INC.-62.31%27
MODERNA, INC.197.32%125 937
LONZA GROUP AG28.34%58 955
IQVIA HOLDINGS INC.44.70%49 527
SEAGEN INC.-9.64%28 937
CELLTRION, INC.-41.09%24 625